IL-1 and anti-inflammatory drugs modulate A β cytotoxicity in PC12 cells

Brain Research

Volumn 723, Issue 1-2, 1996, Pages 231-234

  Fagarasan, Mirela O ^a   Aisen, Paul S ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Chloroquine; Dexamethasone; Indomethacin; Inflammation; Interleukin 1; Amyloid

Indexed keywords

AMYLOID BETA PROTEIN; CHLOROQUINE; DEXAMETHASONE; INDOMETACIN; INTERLEUKIN 1BETA;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; INFLAMMATION; NEUROTOXICITY; NONHUMAN; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; RAT;

AMYLOID BETA-PROTEIN; ANIMALS; ANTI-INFLAMMATORY AGENTS; INTERLEUKIN-1; PC12 CELLS; RATS;

EID: 0030014166     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-8993(96)00259-4     Document Type: Article

References (34)

1. Abraham, C.R., Selkoe, D.J. and Potter, H., Immunohistochemical identification of the serine protease inhibitor alpha-1 antichymotrypsin in the brain amyloid deposits of Alzheimer's disease, Cell, 52 (1988) 487-501.
2. Abraham, C.R., Shirahama, T. and Potter, H., The protease inhibitor α 1-antichymotrypsin is associated solely with amyloid deposits containing the β-protein and is localized in specific cells of both normal and diseased brain, Neurobiol. Aging, 11 (1990) 123-129.
3. Aisen, P.S., Altstiel, L., Marin, D. and Davis, K., Treatment of Alzheimer's disease with prednisone: results of pilot studies and design of multicenter trial, J. Am. Geriatr. Soc., 43 (1995) SA27 (Abstract).
4. Aisen, P.S. and Davis, K.L., Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am J Psychiatry, 151 (1994) 1105-1113.
5. Bannwarth, B., Netter, P., Lapicque, F., Pere, P., Thomas, P. and Gaucher. A., Plasma and cerebrospinal fluid concentrations of indomethacin in humans, Eur. J. Clin. Pharmacol., 38 (1990) 343-346.
6. Bauer, J., Strauss, S., Schreiter-Gasser, U., Ganter, U., Schlegel, P., Witt, I., Yolk, B. and Berger, M., Interleukin-6 and alpha-2-macroglobulin indicate an acute phase response in Alzheimer's disease cortices, FEBS Lett., 285 (1991) 111-114.
7. Burdick, D., Soreghan, B., Kwon, M., Kosmoski, J., Knauer, M., Henschen, A., Yates, J., Cotman, C. and Glabe, C., Assembly and aggregation properties of synthetic Alzheimer's A4/β amyloid peptide analogs, J. Biol. Chem., 267 (1992) 546-554.
8. Dash, P.K. and Moore, A.N., Enhanced processing of APP induced by IL-1β can be reduced by indomethacin and norhydroguaiaretic acid, Biochem. Biophys. Res. Commun., 208 (1995) 542-548.
9. Del Bo, R., Angeretti, N., Lucca, E., De Simoni, M.G. and Forloni, G., Reciprocal control of inflammatory cytokines, IL-1 and IL-6, and beta-amyloid production in cultures, Neurosci. Lett., 188 (1995) 70-74.
10. Eikelenboom, P. and Stam, F.C., Immunoglobulins and complement factors in senile plaques. An immunohistochemical study, Acta Neuropathol. (Berl.) 57 (1982) 239-242.
11. Fagarasan, M., Amyloid β-peptide (1-42) produces hydroxyl radicals: involvement in neurotoxicity (submitted).
12. Gandy, S.E., Caporaso, G.L., Ramabhadran, T.V., Suzuki, T., Buxbaum, J.D., Nordstedt, C., Iverfeldt, K., Czernik, A.J., Nairn, A.C. and Greengard, P., Characterization of alternative routes for processing of the Alzheimer β/A4-amyloid precursor protein: differential effects of phorbol esters and chloroquine, Ann. NY Acad. Sci., 674 (1992) 203-217.
13. Gravina, S.A., Ho, L., Eckman, C.B., Long, K.E. et al., Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42 (43), J. Biol. Chem., 270 (1995) 7013-7016.
14. Haga, S., Akai, K. and Ishii, T., Demonstration of microglial cells in and around senile (neuritic) plaques in the Alzheimer brain: an immunohistochemical study using a novel monoclonal antibody, Acta Neuropathol., 77 (1989) 569-575.
15. HERA Study Group, A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA Study, Am. J. Med., 98 (1995) 156-168.
16. Insel, P., Analgesic-antipyretics and antiinflammatory agents. In A.G. Gilman, T.W. Rall, A.S. Niles and P. Taylor (Eds.), The Pharmacologic Basis of Therapeutics, Pergamon Press, New York, 1990, pp. 638-681.
17. Iwatsubo, T., Mann, D.M., Odaka, A., Suzuki, N. and Ihara, Y., Amyloid beta protein (A beta) deposition: A beta 42 (43) precedes A beta 40 in Down syndrome, Ann. Neurol., 37 (1995) 294-299.
18. Laliberte, R., Perregaux, D., Svensson, L., Pazoles, C.J. and Gabel, C.A., Tenidap modulates cytoplasmic pH and inhibits anion transport in vitro. II. Inhibition of IL-1 beta production from ATP-treated monocytes and macrophages, J. Immunol., 153 (1994) 2168-2179.
19. McGeer, P.L., Akiyama, H., Itagaki, S. and McGeer, E.G., Activation of the classical complement pathway in brain tissue of Alzheimer patients, Neurosci. Lett., 107 (1989) 341-346.
20. McGeer, P.L., Itagaki, S., Tago, H. and McGeer, E.G., Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR, Neurosci. Lett., 79 (1987) 195-200.
21. McGeer, P.L. and Rogers, J., Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease, Neurology, 42 (1992) 447-449.
22. Mrak, R.E., Sheng, J.G. and Griffin, W.S., Glial cytokines in Alzheimer's disease: review and pathogenic implications, Hum. Pathol., 26 (1995) 816-823.
23. Mullins, J.F., Watts, F.L. and Wilson, C.J., Plaquenil in the treatment of lupus erythematosus, J. Am. Med. Assoc., 161 (1956) 879-888.
24. Paulus, H.E., Nonsteroidal Anti-Inflammatory Drugs. In W.N. Kelley, E.D. Harris, S. Ruddy and C.B. Sledge (Eds.), A Textbook of Rheumatology, W.B. Saunders, Philadelphia, 1989.
25. Pollack, S.J., Sadler, I.I., Hawtin, S.R., Tailor, V.J. and Shearman, M.S., Sulfated glycosaminoglycans and dyes attenuate the neurotoxic effects of beta-amyloid in rat PC12 cells, Neurosci. Lett., 184 (1995) 113-116.
26. Rogers, J., Kirby, L.C., Hempelman, S.R., Berry, D.L., McGeer, P.L., Kaszniak, A.W., Zalinski, J., Cofield, M., Mansukhani, L., Willson, P. and Kogan, F., Clinical trial of indomethacin in Alzheimer's disease, Neurology, 43 (1993) 1609-1611.
27. Roher, A.E., Lowenson, J.D., Clarke, S., Woods, A.S., Cotter, R.J., Gowing, E. and Ball, M.J., β-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease, Proc. Natl. Acad. Sci. USA, 90 (1993) 10836-10840.
28. Rozemuller, J.M., Stam, F.C. and Eikelenboom, P., Acute phase proteins are present in amorphous plaques in the cerebral but not in the cerebellar cortex of patients with Alzheimer's disease, Neurosci. Lett., 109 (1990) 75-78.
29. Salmeron, G. and Lipsky, P.E., Immunosuppressive potential of antimalarials, Am. J. Med., 75 (1983) 19-24.
30. Shearman, M.S., Hawtin, S.R. and Tailor, V.J., The intracellular component of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction is specifically inhibited by beta-amyloid peptides, J. Neurochem., 65 (1995) 218-227.
31. Sheng, J.G., Mrak, R.E. and Griffin, W.S.T., Microglial interleukin-1α expresiion in brain regions in Alzheimer's disease: correlation with neuritic plaque distribution, Neuropathol. Appl. Neurobiol., 21 (1995) 290-301.
32. Sperber, K., Quraishi, H., Kalb, T.H., Panja, A., Stecher, V. and Mayer, L., Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-α) and IL-6 in human monocytes and T cells, J. Rheumatol., 20 (1993) 803-808.
33. Vandenabeele, P. and Fiers, W., Is amyloidogenesis during Alzheimer's disease due to an IL-1/IL-6-mediated 'acute phase response' in the brain? Immunol. Today, 12 (1991) 217-219.
34. Younkin, S.G., Evidence that A beta 42 is the real culprit in Alzheimer's disease, Ann. Neurol., 37 (1995) 287-288.